- Home
- ARMP vs FBIO Comparison
ARMP vs FBIO Comparison
Compare ARMP & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- FBIO
- Stock Information
- Founded
- ARMP N/A
- FBIO 2006
- Country
- ARMP United States
- FBIO United States
- Employees
- ARMP N/A
- FBIO N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- FBIO Health Care
- Exchange
- ARMP Nasdaq
- FBIO Nasdaq
- Market Cap
- ARMP 52.1M
- FBIO 58.3M
- IPO Year
- ARMP N/A
- FBIO N/A
- Fundamental
- Price
- ARMP $2.54
- FBIO $1.81
- Analyst Decision
- ARMP Strong Buy
- FBIO Strong Buy
- Analyst Count
- ARMP 1
- FBIO 2
- Target Price
- ARMP $9.00
- FBIO $21.00
- AVG Volume (30 Days)
- ARMP 13.2K
- FBIO 214.8K
- Earning Date
- ARMP 08-12-2025
- FBIO 08-12-2025
- Dividend Yield
- ARMP N/A
- FBIO N/A
- EPS Growth
- ARMP N/A
- FBIO N/A
- EPS
- ARMP N/A
- FBIO N/A
- Revenue
- ARMP $4,699,000.00
- FBIO $57,784,000.00
- Revenue This Year
- ARMP $8.43
- FBIO $51.59
- Revenue Next Year
- ARMP N/A
- FBIO $44.74
- P/E Ratio
- ARMP N/A
- FBIO N/A
- Revenue Growth
- ARMP 14.24
- FBIO N/A
- 52 Week Low
- ARMP $0.90
- FBIO $1.33
- 52 Week High
- ARMP $2.96
- FBIO $2.36
- Technical
- Relative Strength Index (RSI)
- ARMP 65.04
- FBIO 41.92
- Support Level
- ARMP $2.14
- FBIO $1.90
- Resistance Level
- ARMP $2.61
- FBIO $2.02
- Average True Range (ATR)
- ARMP 0.14
- FBIO 0.09
- MACD
- ARMP -0.00
- FBIO -0.02
- Stochastic Oscillator
- ARMP 81.08
- FBIO 15.38
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.